Durch Strahlentherapie aktiviertes NBTXR3 zur Behandlung von lokal fortgeschrittenem oder grenzwertig resezierbarem Bauchspeicheldrüsenkrebs
Phase-I-Studie zu NBTXR3, aktiviert durch Strahlentherapie bei lokal fortgeschrittenem oder grenzwertig resezierbarem duktalem Adenokarzinom des Pankreas
To find the recommended dose of NBTXR3 that can be given in combination with radiation therapy to patients with pancreatic cancer. To learn if the dose NBTXR3 found in Part 1 can help to control the disease.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
PRIMARY OBJECTIVE:
• To determine the recommended phase II dose (RP2D) of NBTXR3 activated by radiotherapy in subjects with locally advanced or borderline-resectable pancreatic ductal adenocarcinoma.
SECONDARY OBJECTIVES:
- To evaluate the safety and feasibility of NBTXR3 intratumoral injection activated by radiotherapy in locally advanced or borderline-resectable pancreatic ductal adenocarcinoma
- To evaluate the anti-tumor response of NBTXR3 intratumoral injection activated by radiotherapy in subjects with locally advanced or borderline-resectable pancreatic ductal adenocarcinoma
- To evaluate time-to-event outcomes in subjects with locally advanced or borderline-resectable pancreatic ductal adenocarcinoma
EXPLORATORY OBJECTIVES:
- To evaluate the body kinetic profile of intratumorally injected NBTXR3.
- To evaluate time to event outcomes for subjects with clinical staging of locally advanced, unresectable disease.
- To evaluate resectability conversion rates.
- To evaluate surgical outcomes in subjects who undergo surgery after radiation therapy.
- To associate radiomic measurements with outcomes.
- To evaluate biomarkers of response in subjects treated with NBTXR3/RT.
OUTLINE: This is a dose-escalation study of NBTXR3.
Patients receive NBTXR3 intratumorally (IT) on day 1. Patients then undergo 15 fractions of intensity modulated radiation therapy (IMRT) between days 15-43 in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 1 month and then every 3 months for up to 1 year.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030
- M D Anderson Cancer Center
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
1. Signed informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study 2. Age ≥ 18 years 3. Biopsy proven ductal adenocarcinoma of the pancreas,as defined by the following:
a. Borderline resectable pancreatic adenocarcinoma (BRPC) has no aortic involvement with at least ONE of the following features: i. Superior mesenteric vein (SMV) or Portal vein (PV) with a tumor interface of ≥ 180° OR short segment occlusion of SMV or PV amenable to reconstruction ii. Superior mesenteric artery (SMA) or celiac axis (CA) with a tumor interface of < 180° iii. Any degree of hepatic artery interface that is amenable to reconstruction b. Locally advanced pancreatic adenocarcinoma (LAPC) has at least ONE of the following features:
-
Signed informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study
-
Age ≥ 18 years
-
Biopsy proven ductal adenocarcinoma of the pancreas,as defined by the following:
a. Borderline resectable pancreatic adenocarcinoma (BRPC) has no aortic involvement with at least ONE of the following features: i. Superior mesenteric vein (SMV) or Portal vein (PV) with a tumor interface of ≥ 180° OR short segment occlusion of SMV or PV amenable to reconstruction ii. Superior mesenteric artery (SMA) or celiac axis (CA) with a tumor interface of < 180° iii. Any degree of hepatic artery interface that is amenable to reconstruction b. Locally advanced pancreatic adenocarcinoma (LAPC) has at least ONE of the following features: i. Occlusion of the SMV or PV that is not amenable to reconstruction ii. Tumor interface of the superior mesenteric artery or celiac axis ≥ 180° iii. Involvement of the hepatic artery that is not amenable to reconstruction iv. Involvement of the aorta
-
Has had a 4-month course (± 2-months) of chemotherapy for PDAC without radiographic evidence of distant metastatic disease. Following chemotherapy regimens are allowed:
- gemcitabine/nab-paclitaxel
- gemcitabine/capecitabine
- gemcitabine/cisplatin
- gemcitabine
- FOLFOX
- FOLFIRINOX
-
Amenable to undergo the endoscopic ultrasound guided injection of NBTXR3 as per investigator or treating physician.
-
Has a target lesion in the pancreas that is identifiable on cross sectional imaging by repeated measurements (via RECIST 1.1) at the same anatomical location
a. Nodal disease only is not allowed.
-
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
-
Laboratory Values at screening:
- Hemoglobin ≥ 8.0 g/dL
- Absolute Neutrophil Count (ANC) ≥ 1,500/mm3
- Platelet Count ≥ 100,000/mm3
- Creatinine ≤ 1.5 x upper limit of normal (ULN)
- Total Bilirubin ≤ 2.0 mg/dL
- AST / ALT ≤ 3.0 x upper limit of normal (ULN)
- Serum albumin ≥ 3.0 g/dL
-
Negative pregnancy test ≤ 7 days prior to NBTXR3 injection in all females of child-bearing potential
-
If participant has a history of prior duodenal or biliar plastic stent, it should be replaced with a metal stent ≥ 1 week prior to Study Day 1.
Exclusion Criteria:
-
Prior radiation therapy to the upper abdomen
-
Prior surgical resection of pancreatic tumor
-
Diagnosis other than pancreatic ductal adenocarcinoma. All other histologic types (i.e., adenosquamous, cystadenocarcinoma, etc.) are not eligible to participate on this study.
-
LAPC or BRPC with radiographic evidence of distant metastasis at screening.
-
Has received any approved or investigational anti-neoplastic agent other than the chemotherapies specified in this protocol (i.e. chemotherapies included in Inclusion #4)
-
Known uncontrolled (Grade ≥ 2) or active gastric or duodenal ulcer disease within 30 days of enrollment
-
Known contraindication to iodine-based or gadolinium-based IV contrast
-
Active malignancy, in addition to pancreatic cancer, with the exception of basal cell carcinoma of the skin definitively treated and relapse free within at least 1 year from diagnosis
-
Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes, second or third degree atrioventricular heart block without a permanent pacemaker in place)
-
Class III or IV Congestive Heart Failure as defined by the New York Heart Association functional classification system <6 months prior to screening
-
Known active, uncontrolled (high viral load) HIV or hepatitis B or hepatitis C infection
a. Patients who have been vaccinated for hepatitis B and do not have a history of infection are eligible.
-
Female patients who are pregnant or breastfeeding
-
Women of child-bearing potential and their male partners who are unwilling or unable to use an acceptable method of birth control for the entire study period. Acceptable methods of contraception are those that, alone or in combination, result in a failure rate of < 1% per year when used consistently and correctly
-
Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Treatment (NBTXR3, radiation therapy)
Patients receive NBTXR3 IT on day 1. Patients then undergo 15 fractions of radiation therapy between days 15-43 in the absence of disease progression or unacceptable toxicity. |
Undergo radiation therapy
Andere Namen:
Given IT
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Empfohlene Phase-II-Dosis (RP2D)
Zeitfenster: Bis zu 1 Jahr
|
Bis zu 1 Jahr
|
|
|
Dose-limiting toxicities
Zeitfenster: 4 weeks after last radiation dose
|
Any grade >= 3 adverse event related to NBTXR3 and/or radiation therapy. Any toxicity (grade >= 3) that is at least possibly related to study drug (NBTXR3) is a DLT. Adverse events will be scored based on National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE v 5.0). |
4 weeks after last radiation dose
|
|
Maximum tolerated dose (MTD)
Zeitfenster: Up to 1 year
|
MTD will be determined as the dose for which the isotonic estimate of the toxicity rate is closest to the target toxicity rate 30%. |
Up to 1 year
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progressionsfreies Überleben (PFS)
Zeitfenster: Von der NBTXR3-Injektion bis zu lokalem Rezidiv, lokaler Progression, entfernter Progression oder Tod jeglicher Ursache, je nachdem, was zuerst eintritt, bewertet bis zu 1 Jahr
|
Von der NBTXR3-Injektion bis zu lokalem Rezidiv, lokaler Progression, entfernter Progression oder Tod jeglicher Ursache, je nachdem, was zuerst eintritt, bewertet bis zu 1 Jahr
|
|
|
Gesamtüberleben (OS)
Zeitfenster: Von der NBTXR3-Injektion bis zum Tod jeglicher Ursache oder EoS, je nachdem, was zuerst eintritt, bewertet bis zu 1 Jahr
|
Von der NBTXR3-Injektion bis zum Tod jeglicher Ursache oder EoS, je nachdem, was zuerst eintritt, bewertet bis zu 1 Jahr
|
|
|
Determination of the feasibility of NBTXR3 injection in pancreas
Zeitfenster: Up to 1 year
|
Feasibility refers to the ability to do intratumoral injection of NBTXR3. The outcome for each patient would be "feasible" or "not feasible." |
Up to 1 year
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Anteil lokal fortgeschrittener Probanden, die sich nach Erhalt von NBTXR3/Strahlentherapie einer chirurgischen Resektion unterziehen (R3/RT)
Zeitfenster: Bis zu 1 Jahr
|
Bis zu 1 Jahr
|
|
|
Presence of hafnium
Zeitfenster: Up to 1 year
|
Will evaluation of the time-course dependent presence of hafnium in blood and urine following NBTXR3 intratumoral injection. |
Up to 1 year
|
|
Disease control rate
Zeitfenster: 6 months
|
Defined as the proportion of patients without progression 6 months post NBTXR3 injection. |
6 months
|
|
Resection status
Zeitfenster: Up to 1 year
|
Resection status as assessed macroscopically by surgeon R0- Macroscopically complete tumor removal with negative microscopic surgical margins, R1- Macroscopically complete tumor removal with positive microscopic margins (any or all), and R2- Macroscopically incomplete tumor removal with known or suspected residual gross disease. |
Up to 1 year
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Eugene J Koay, M.D. Anderson Cancer Center
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des endokrinen Systems
- Neubildungen nach Standort
- Neubildungen
- Neoplasmen des Verdauungssystems
- Erkrankungen des Verdauungssystems
- Neoplasmen der endokrinen Drüse
- Erkrankungen der Bauchspeicheldrüse
- Neoplasmen der Bauchspeicheldrüse
- Therapeutika
- Physikalische Phänomene
- Strahlentherapie
- Strahlung
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 2019-1001
- 2019-1001 (Andere Kennung: M D Anderson Cancer Center)
- NCI-2020-03731 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .